Mazdutide
A once-weekly dual glucagon (GCG) and GLP-1 receptor agonist. It was approved in China in June 2025 for weight management but is not approved in the US or EU.
- Half-life
- 5.0 d
- Out of system
- ~4 weeks
- Route
- Subcutaneous
- Level
- Advanced
Long-acting — weekly dosing keeps levels steady. After the last dose, roughly 97% has cleared in ~4 weeks (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What Mazdutide is used for
- Dual glucagon and GLP-1 action drives weight loss while boosting energy expenditure
- Once-weekly subcutaneous dosing with strong Phase 3 weight-reduction data
- May offer additional metabolic benefits from the glucagon component
How it's typically used
Trial and label range: titrated to about 6 mg subcutaneously once weekly for weight management, as reported in the literature.
What to watch for
- GI side effects and possible increases in heart rate can occur
- Glucagon agonism can affect glucose handling and requires monitoring
- Approved only in China (June 2025); not approved in the US or EU
Common questions
- What is the half-life of Mazdutide?
- Mazdutide has an approximate elimination half-life of 5.0 d. Long-acting — weekly dosing keeps levels steady.
- How long does Mazdutide stay in your system?
- Roughly 97% of a dose has cleared after five half-lives — about ~4 weeks for Mazdutide. That is the window that matters for washouts, bloodwork and surgery.
- How is Mazdutide taken?
- Mazdutide is typically administered by the subcutaneous route. Trial and label range: titrated to about 6 mg subcutaneously once weekly for weight management, as reported in the literature.
- What are the risks of Mazdutide?
- GI side effects and possible increases in heart rate can occur Glucagon agonism can affect glucose handling and requires monitoring Approved only in China (June 2025); not approved in the US or EU
About GLP-1 & weight loss
- What they are
- Incretin analogues — GLP-1 and dual/triple agonists. They slow stomach emptying and act on appetite centres in the brain, so you eat less without white-knuckling it.
- How they're run
- One subcutaneous shot a week for most, on the same day each week. Doses climb in steps every four weeks; that slow titration is what keeps side effects tolerable.
- What to watch
- Nausea, constipation, and reflux are near-universal in the first month. Muscle is lost alongside fat unless you keep protein high and keep lifting. Tell any surgeon or anaesthetist you are on one.
Full guide
Mazdutide: A Tracking Guide for a Glucagon and GLP-1 Dual Agonist
A neutral, harm-reduction guide to mazdutide, a dual glucagon/GLP-1 agonist approved in China, and what to monitor.
Other glp-1 & weight loss
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.